Encephalopathy Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Encephalopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting

Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)

Progressive Multifocal Leukoencephalopathy
National Institute of Neurological Disorders and Stroke (NINDS)700 enrolled1 locationNCT01730131
Recruiting
Phase 1

Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy

Multiple SclerosisProgressive Multifocal Leukoencephalopathy
National Institute of Neurological Disorders and Stroke (NINDS)15 enrolled1 locationNCT05849467
Recruiting
Not Applicable

Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy

Alzheimer DiseaseCognitive AbnormalityAlzheimer Dementia+2 more
Covenant Health, US30 enrolled6 locationsNCT07222280
Recruiting

The Myelin Disorders Biorepository Project

AdrenoleukodystrophyCockayne SyndromeRefsum Disease+63 more
Children's Hospital of Philadelphia12,000 enrolled23 locationsNCT03047369
Recruiting

VICIS - Vienna Cirrhosis Study

AscitesLiver CirrhosisPortal Hypertension+2 more
Medical University of Vienna10,000 enrolled1 locationNCT03267615
Recruiting
Not Applicable

Affect of Melatonin on Sleep and Cognition in Cirrhosis

CirrhosisHepatic EncephalopathyCovert Hepatic Encephalopathy+1 more
Weill Medical College of Cornell University18 enrolled1 locationNCT07046429
Recruiting
Phase 3

Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease

Alzheimer DiseaseChronic Traumatic Encephalopathy
CereMark Pharma, LLC230 enrolled1 locationNCT06254469
Recruiting
Not Applicable

Neurologic Stem Cell Treatment Study

Cognitive ImpairmentDementiaTraumatic Brain Injury+23 more
MD Stem Cells500 enrolled3 locationsNCT02795052
Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Multiple Endocrine Neoplasia Type 1Multiple Endocrine Neoplasia Type 2Rare Disorders+337 more
Sanford Health20,000 enrolled2 locationsNCT01793168
Recruiting

Neuroimmunology Registry and Biobank

EpilepsyMovement DisordersSpasticity+5 more
Charite University, Berlin, Germany300 enrolled2 locationsNCT06958341
Recruiting
Early Phase 1

[18F]ACI-19626 PET in TDP-43 Proteinopathies

Amyotrophic Lateral Sclerosis(ALS)Alzheimer's Disease(AD)Frontotemporal Dementia (FTD)+2 more
AC Immune SA45 enrolled1 locationNCT06891716
Recruiting
Phase 4

Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose

Liver DiseasesCirrhosis, LiverPortal Hypertension+2 more
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)238 enrolled6 locationsNCT04073290
Recruiting
Not Applicable

Safety and Efficacy of Fecal Microbiota Transplantation

AlopeciaDiabetes MellitusObesity+24 more
Chinese University of Hong Kong450 enrolled1 locationNCT04014413
Recruiting

HIV-HEART Aging Study

Heart FailureWeight GainCoronary Disease+4 more
University Hospital, Essen2,000 enrolled5 locationsNCT04330287
Recruiting
Phase 1

ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.

CARLymphoblastic Leukemia in ChildrenLymphoblastic Leukemia+3 more
National University Hospital, Singapore40 enrolled1 locationNCT05038696
Recruiting
Phase 1

CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia

CARRefractory LeukemiaLymphoblastic Leukemia in Children+4 more
National University Hospital, Singapore20 enrolled1 locationNCT05043571
Recruiting

Posterior Reversible Encephalopathy Syndrome in the Critically Ill Patients

Posterior Reversible Encephalopathy Syndrome
Ictal Group300 enrolled1 locationNCT03470467